The Pathogenesis of Bacterial Lung Infections

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Bacterial Pathogens".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 6872

Special Issue Editor


E-Mail Website
Guest Editor
Division of Pulmonary, Critical Care & Sleep, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
Interests: lung immune response; mechanism of lung injury

Special Issue Information

Bacterial lung infections continue to be a major cause of morbidity and mortality worldwide. The lungs are under constant pressure to protect the body from invading bacteria. An effective inflammatory immune response must be tightly orchestrated to ensure clearance of any invading bacteria, while simultaneously ensuring that inflammation is kept under control.  Pneumonia and sepsis are major threats to human life, especially as their treatment has become more difficult with emerging drug resistance. In order to survive within the lung, bacteria target the host immune system to prevent eradication. Many bacteria directly target inflammatory cells and cytokines to impair inflammatory responses. However, bacteria can also take advantage of and attenuate inflammatory immune responses in the host lung to inhibit bacterial elimination. It is critical we define mechanisms of resistance and establish an improved improved understanding of the host factors that can be modulated to develop novel therapeutic approaches to infections.

For this Special Issue of Pathogens, we invite the submission of original research articles, case reports, short communications, and review articles focused on “Bacterial Lung Infections” with the goal of enhancing our understanding of lung infection pathogenesis, including bacterial and host factors that determine the outcome of infections. In particular, we seek to identify novel approaches that enhance host factors for bacterial clearance and can be integrated into new therapeutic approaches. Topics of interest include: host factors, such as alcohol and smoking; immunocompromised states; microbiome and microbial community dynamics; bacterial resistance mechanisms; hospital-acquired bacterial infections; multidrug resistant infections; innate and adaptive responses; lipid mediators and mitochondrial dysfunction; new infection models of lung infections; and novel therapeutics.

We encourage the submission of articles, communications, and reviews focused on the mechanisms of pathogenesis or novel compounds intended to mitigate it. All submitted papers will undergo a standard independent peer-review process.

Prof. Dr. Ruxana T. Sadikot
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bacterial lung infections
  • pathogenesis
  • bacterial resistance mechanisms
  • novel therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 14680 KiB  
Article
The Inherited Intestinal Microbiota from Myeloid-Specific ZIP8KO Mice Impairs Pulmonary Host Defense against Pneumococcal Pneumonia
by Derrick R. Samuelson, Deandra R. Smith, Kelly C. Cunningham, Sabah Haq, Daniel N. Villageliú, Christi M. Ellis, Niaz Bahar Chowdhury, Amanda E. Ramer-Tait, Jeffrey D. Price and Daren L. Knoell
Pathogens 2023, 12(5), 639; https://doi.org/10.3390/pathogens12050639 - 25 Apr 2023
Cited by 1 | Viewed by 1885
Abstract
Intestinal dysbiosis increases susceptibility to infection through the alteration of metabolic profiles, which increases morbidity. Zinc (Zn) homeostasis in mammals is tightly regulated by 24 Zn transporters. ZIP8 is unique in that it is required by myeloid cells to maintain proper host defense [...] Read more.
Intestinal dysbiosis increases susceptibility to infection through the alteration of metabolic profiles, which increases morbidity. Zinc (Zn) homeostasis in mammals is tightly regulated by 24 Zn transporters. ZIP8 is unique in that it is required by myeloid cells to maintain proper host defense against bacterial pneumonia. In addition, a frequently occurring ZIP8 defective variant (SLC39A8 rs13107325) is strongly associated with inflammation-based disorders and bacterial infection. In this study, we developed a novel model to study the effects of ZIP8-mediated intestinal dysbiosis on pulmonary host defense independent of the genetic effects. Cecal microbial communities from a myeloid-specific Zip8 knockout mouse model were transplanted into germ-free mice. Conventionalized ZIP8KO-microbiota mice were then bred to produce F1 and F2 generations of ZIP8KO-microbiota mice. F1 ZIP8KO-microbiota mice were also infected with S. pneumoniae, and pulmonary host defense was assessed. Strikingly, the instillation of pneumococcus into the lung of F1 ZIP8KO-microbiota mice resulted in a significant increase in weight loss, inflammation, and mortality when compared to F1 wild-type (WT)-microbiota recipients. Similar defects in pulmonary host defense were observed in both genders, although consistently greater in females. From these results, we conclude that myeloid Zn homeostasis is not only critical for myeloid function but also plays a significant role in the maintenance and control of gut microbiota composition. Further, these data demonstrate that the intestinal microbiota, independent of host genetics, play a critical role in governing host defense in the lung against infection. Finally, these data strongly support future microbiome-based interventional studies, given the high incidence of zinc deficiency and the rs13107325 allele in humans. Full article
(This article belongs to the Special Issue The Pathogenesis of Bacterial Lung Infections)
Show Figures

Figure 1

Review

Jump to: Research

12 pages, 657 KiB  
Review
Bacterial Pathogens Causing Pneumonia Post Hematopoietic Stem Cell Transplant: The Chronic GVHD Population
by Said Chaaban, Andrea Zimmer, Vijaya Raj Bhatt, Cynthia Schmidt and Ruxana T. Sadikot
Pathogens 2023, 12(5), 726; https://doi.org/10.3390/pathogens12050726 - 17 May 2023
Cited by 1 | Viewed by 1981
Abstract
Allogeneic stem cell transplantation is a lifesaving treatment for many malignancies. Post-transplant patients may suffer from graft versus host disease in the acute and/or the chronic form(s). Post-transplantation immune deficiency due to a variety of factors is a major cause of morbidity and [...] Read more.
Allogeneic stem cell transplantation is a lifesaving treatment for many malignancies. Post-transplant patients may suffer from graft versus host disease in the acute and/or the chronic form(s). Post-transplantation immune deficiency due to a variety of factors is a major cause of morbidity and mortality. Furthermore, immunosuppression can lead to alterations in host factors that predisposes these patients to infections. Although patients who receive stem cell transplant are at an increased risk of opportunistic pathogens, which include fungi and viruses, bacterial infections remain the most common cause of morbidity. Here, we review bacterial pathogens that lead to pneumonias specifically in the chronic GVHD population. Full article
(This article belongs to the Special Issue The Pathogenesis of Bacterial Lung Infections)
Show Figures

Figure 1

10 pages, 262 KiB  
Review
Bacterial Infections Associated with Immunosuppressive Agents Commonly Used in Patients with Interstitial Lung Diseases
by Said Chaaban and Ruxana T. Sadikot
Pathogens 2023, 12(3), 464; https://doi.org/10.3390/pathogens12030464 - 15 Mar 2023
Cited by 1 | Viewed by 2304
Abstract
There are about 200 different types of interstitial lung disease (ILD), and a crucial initial step in the assessment of a patient with suspected ILD is achieving an appropriate diagnosis. Some ILDs respond to immunosuppressive agents, while immunosuppression can be detrimental in others, [...] Read more.
There are about 200 different types of interstitial lung disease (ILD), and a crucial initial step in the assessment of a patient with suspected ILD is achieving an appropriate diagnosis. Some ILDs respond to immunosuppressive agents, while immunosuppression can be detrimental in others, hence treatment is based on the most confident diagnosis with consideration of a patient’s risk factors. Immunosuppressive medications have the potential to result in substantial, and perhaps life-threatening, bacterial infections to a patient. However, data on the risk of bacterial infections from immunosuppressive treatment specifically in patients with interstitial lung disease is lacking. We hereby review the immunosuppressive treatments used in ILD patients excluding sarcoidosis, highlight their risk of bacterial infections, and discuss the potential mechanisms that contribute to the increased risk of infections. Full article
(This article belongs to the Special Issue The Pathogenesis of Bacterial Lung Infections)
Back to TopTop